Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Lymphoid 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Carcinoid Tumor 1Adrenocortical Carcinoma 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 3surufatinib 2pembrolizumab 2olaparib 2lanreotide 2atezolizumab 2Everolimus 23-Iodobenzylguanidine 2tivozanib 1tislelizumab 1repotrectinib 1regorafenib 1pralsetinib 1irinotecan sucrosofate 1cabozantinib 1avelumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1Tirapazamine 1Temozolomide 1TKM-080301 1S 1 (combination) 1Radiotherapy 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1PM 01183 1Ondansetron 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × TKM-080301 × NET × Clear all
NCT01262235 2019-01-16

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Arbutus Biopharma Corporation

Phase 1/2 Completed
68 enrolled
EndocrineLymphoidNET

Carcinoid Tumor, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡